Used primarily in the treatment of advanced renal cell carcinoma (kidney cancer), Pazopanib is a targeted therapy that inhibits multiple tyrosine kinases involved in tumor angiogenesis, growth, and progression. It blocks key receptors such as VEGFR, PDGFR, and c-Kit, thereby disrupting the signaling pathways that promote blood vessel formation and cancer cell proliferation. This helps slow tumor growth and spread. It is also used in certain soft tissue sarcomas, offering an oral treatment option for patients who have not responded to prior chemotherapy. Its targeted mechanism allows for more specific action against cancer cells with potentially fewer side effects compared to traditional chemotherapy.